Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI
- Written by PR Newswire
Highlights:
- ISM001-055 was safe and well-tolerated with a favorable PK profile in IPF patients
- Patients who received ISM001-055 showed dose-dependent improvement in the efficacy endpoint, as measured by change in forced vital capacity (FVC) at 12 weeks
CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage...














